Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Incy crawled time : 01:00 save search
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published: 2023-12-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.77%
H: 0.49%
C: 0.49%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: -0.2%
H: 1.7%
C: 1.3%
rient-16 treatment results study
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
Published: 2023-11-24 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.69%
H: 1.66%
C: 1.66%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.34%
H: 0.37%
C: 0.3%
ibi351 drug granted review designation medical application china
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
Published: 2023-05-11 (Crawled : 01:00) - prnewswire.com
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.18%
H: 0.03%
C: -0.26%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.3%
H: 0.12%
C: 0.09%
ibi362 obesity chinese study
Innovent Announces 2022 Annual Results and Business Updates
Published: 2023-03-29 (Crawled : 01:00) - prnewswire.com
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.4%
H: 0.23%
C: -0.92%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.6%
H: 0.69%
C: 0.58%
business results
Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023
Published: 2023-03-21 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.24%
H: 0.01%
C: -0.99%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.13%
H: 0.34%
C: -1.12%
trials meeting
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
Published: 2023-03-14 (Crawled : 01:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.28%
H: 0.38%
C: 0.31%
XNCR | $18.19 -1.03% -1.04% 490K
|
Health Technology
|
| O: 1.2%
H: 0.17%
C: -1.67%
MOR | News | $17.97 -0.06% -0.06% 330K
|
Health Technology
|
| O: -1.79%
H: 3.39%
C: 3.39%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.18%
H: 1.06%
C: 0.94%
meeting
Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy
Published: 2023-02-15 (Crawled : 01:00) - prnewswire.com
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.49%
H: 0.29%
C: -3.13%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.38%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: -0.45%
H: 0.48%
C: 0.44%
ibi311 thyroid study
Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
Published: 2023-01-05 (Crawled : 01:00) - prnewswire.com
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.59%
H: 0.15%
C: -0.56%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -3.07%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: -0.63%
H: 2.86%
C: 2.01%
ibi351 designation lung therapy cancer
Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease
Published: 2022-12-15 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.78%
H: 0.92%
C: -0.18%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: -0.83%
H: 0.66%
C: 0.3%
treatment disease collaboration
Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
Published: 2022-12-09 (Crawled : 01:00) - prnewswire.com
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.05%
H: 0.4%
C: -2.15%
ibi939 medical
Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
Published: 2022-12-09 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.33%
H: 0.27%
C: -3.22%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.05%
H: 0.4%
C: -2.15%
ibi110 medical update
Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)
Published: 2022-12-05 (Crawled : 01:00) - prnewswire.com
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.27%
H: 0.4%
C: -1.2%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: -0.43%
H: 2.17%
C: 1.58%
ibi353 chinese therapeutics study
Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings
Published: 2022-11-28 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.57%
H: 1.04%
C: -1.87%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.49%
H: 1.67%
C: 0.64%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.05%
H: 0.89%
C: -0.6%
trials
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity
Published: 2022-11-15 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.25%
H: 0.01%
C: -1.96%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 1.37%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: -1.86%
ibi362 obesity chinese study
Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting
Published: 2022-11-14 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.6%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 1.92%
H: 0.48%
C: -0.84%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.22%
H: 0.86%
C: -0.79%
ibi351 meeting chinese tumors study
Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022
Published: 2022-11-07 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.01%
H: 0.88%
C: 0.88%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.17%
H: 2.51%
C: 1.97%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -2.05%
ibi306 sessions chinese heart results study hypercholesterolemia
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors
Published: 2022-10-31 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: -5.14%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.35%
H: 1.47%
C: 0.96%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: -0.84%
H: 1.0%
C: 0.5%
ibi343 australia tumors study
Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine
Published: 2022-10-17 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.42%
H: 1.44%
C: -0.01%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.51%
H: 0.95%
C: 0.65%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.9%
H: 1.42%
C: 0.92%
ibi362 obesity chinese results
The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma
Published: 2022-10-10 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.13%
H: 0.24%
C: -0.72%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.2%
H: 0.1%
C: -1.43%
cyramza treatment approved china
The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
Published: 2022-10-10 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: -0.13%
H: 0.24%
C: -0.72%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.2%
H: 0.1%
C: -1.43%
treatment lung thyroid china
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.